Multiple myeloma:: Monoallelic deletions of the tumor suppressor genes TP53 and RB1 in long-term follow-up

被引:10
作者
Carlebach, M
Amiel, A [1 ]
Gaber, E
Radnay, J
Manor, Y
Fejgin, M
Lishner, M
机构
[1] Meir Hosp, Genet Inst, IL-44281 Kfar Saba, Israel
[2] Meir Hosp, Hematol Lab, IL-44281 Kfar Saba, Israel
[3] Meir Hosp, Dept Med, IL-44281 Kfar Saba, Israel
[4] Meir Hosp, Dept Hematol, IL-44281 Kfar Saba, Israel
[5] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
关键词
D O I
10.1016/S0165-4608(99)00144-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recently, a working-model of a stepwise malignant transformation in the molecular pathogenesis of multiple myeloma (MM) was proposed. involving the tumor suppressor gene TP53 and retinoblastoma gene (RB1) as prominent components of cell cycle control. To further define the role of TP53 and RB1 in disease progression, we retrospectively analyzed by fluorescence in situ hybridization (FISH) cytological material from 16 patients who underwent sequential bone marrow biopsies during the course of their disease. For TP53, no deletions were detected at presentation or during follow-up. It is possible that the patients reported here represent a subset with relatively long survival, and therefore did nor demonstrate the TP53 deletions that had been reported in patients with a very poor prognosis. For RBI, monoallelic deletion was demonstrated in nine patients. In each case, the deletion appeared already in the first biopsy analyzed. The presence of a deletion did not affect the rate of tumor progression or the length of follow-up, and thus prognosis. Monoallelic deletions of RBI appear to be a frequent and early event in the pathogenesis of MM, without obvious relevance for disease progression. (C) Elsevier Science Inc., 2000. All rights reserved.
引用
收藏
页码:57 / 60
页数:4
相关论文
共 15 条
[1]   THE ONCOPROTEIN PHENOTYPE OF PLASMA-CELLS FROM PATIENTS WITH MULTIPLE-MYELOMA [J].
BROWN, RD ;
POPE, B ;
LUO, XF ;
GIBSON, J ;
JOSHUA, D .
LEUKEMIA & LYMPHOMA, 1994, 16 (1-2) :147-156
[2]  
DAO DD, 1994, LEUKEMIA, V8, P1280
[3]  
DRACH J, 1995, CANCER RES, V55, P3854
[4]   Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy [J].
Drach, J ;
Ackermann, J ;
Fritz, E ;
Krömer, E ;
Schuster, R ;
Gisslinger, H ;
DeSantis, M ;
Zojer, N ;
Fiegl, M ;
Roka, S ;
Schuster, J ;
Heinz, R ;
Ludwig, H ;
Huber, H .
BLOOD, 1998, 92 (03) :802-809
[6]  
Flactif M, 1995, LEUKEMIA, V9, P2109
[7]   Multiple myeloma: Increasing evidence for a multistep transformation process [J].
Hallek, M ;
Bergsagel, PL ;
Anderson, KC .
BLOOD, 1998, 91 (01) :3-21
[8]  
JUGEMORINEAU N, 1995, BRIT J HAEMATOL, V91, P664
[9]   The retinoblastoma susceptibility gene RB-1 in multiple myeloma [J].
JugeMorineau, N ;
Harousseau, JL ;
Amiot, M ;
Bataille, R .
LEUKEMIA & LYMPHOMA, 1997, 24 (3-4) :229-237
[10]   IMPROVED CYTOGENETICS IN MULTIPLE-MYELOMA - A STUDY OF 151 PATIENTS INCLUDING 117 PATIENTS AT DIAGNOSIS [J].
LAI, JL ;
ZANDECKI, M ;
MARY, JY ;
BERNARDI, F ;
IZYDORCZYK, V ;
FLACTIF, M ;
MOREL, P ;
JOUET, JP ;
BAUTERS, F ;
FACON, T .
BLOOD, 1995, 85 (09) :2490-2497